← Back to Calendar

Geron Corporation Q4 2025 Earnings

Geron Corporation · $GERN
Standard Review Earnings
Catalyst Date
February 25, 2026
Date Status
47d ago (past)
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$1.67 +28.46%
+$0.37 today
Day: $1.66 – $1.78
Market Cap
N/A
Shares out: 640.90M
Float: 510.78M
52-Week Range
$1.04
$2.01
Current price is at 65% of 52-week range
Avg Volume
18.04M
Beta
0.67
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $GERN catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + RYTELO Rytelo commercial update

Key Notes

Q4 2025 earnings reported February 25, 2026. RYTELO Q4 revenue $48.0M (FY2025 $183.6M). 2026 revenue guidance $220M–$240M. Cash $401M. IMpactMF Phase 3 in myelofibrosis — interim OS analysis expected 2H 2026. sBLA for MDS label expansion PDUFA April 15, 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar